Nearly 40 million Americans have diabetes, and nearly half of those are people who have Type 2 diabetes and are aged 65 or older. This population has a higher risk of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

These devices are increasingly popular in diabetes management and health monitoring. As previously announced, Trinity Biotech has entered into a non-binding Letter of Intent with Bayer for the launch ...

Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

The FDA has cleared Senseonics and Ascensia Diabetes Care's Eversense 365 Glucose Monitoring System. This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy be ...